Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are increasing globally. Treatment options for these patients are very limited. Although treatment of these patients with standardized regimen is associated with high mortality and morbidity, rational usage of new drugs might be promising. In this study we will review epidemiology of XDR-TB and TDR-TB in Iran and the world
